局限性前列腺癌局灶治疗的前瞻性研究系统综述与荟萃分析
该系统综述与荟萃分析纳入50项前瞻性研究共4615例临床局限性前列腺癌患者,评估局灶治疗的肿瘤学与安全性结局。12个月和24个月活检证实临床显著前列腺癌无复发生存率分别为86%和81%,5年免根治/全身治疗生存率82%,≥3级不良事件汇总发生率3%。
要点
- 12个月和24个月csPCa无复发生存率分别为86%和81%。
- 中危亚组12个月csPCa无复发生存率为79%。
- 5年免根治/全身治疗生存率82%,≥3级不良事件发生率3%。
核心结论
- 前瞻性研究短期数据显示,局灶治疗对临床局限性前列腺癌提供中至高的肿瘤控制且安全性良好。
研究设计与样本
- 系统检索PubMed、Scopus和Web of Science数据库,纳入报告初治临床局限性前列腺癌局灶治疗肿瘤学结局的前瞻性研究。
- 共分析50项研究、4615例接受局灶治疗的患者;19项以中危为主(n=2800),16项为低/中危混合(n=990),15项为低危(n=825)。
- 主要终点为活检证实临床显著前列腺癌(csPCa,ISUP分级组≥2)无复发生存率(csPCa RFS)。
主要发现
- 12个月和24个月csPCa RFS率分别为86%(95%CI 82-89%)和81%(95%CI 74-86%)。
- 中危亚组12个月csPCa RFS率为79%(95%CI 74-83%)。
- 5年免根治和全身治疗生存率为82%(95%CI 75-88%)。
- ≥3级不良事件汇总发生率为3%(95%CI 2-5%)。
- 需使用护垫的尿失禁增加3%(95%CI 0-6%),11%的患者出现新发勃起功能障碍(95%CI 4-18%)。
临床怎么用
- 局灶治疗可作为临床局限性前列腺癌的选择之一,但应在前瞻性注册研究或临床试验框架内进行。
- 咨询时应告知患者短期肿瘤控制中至高、严重不良事件风险低,但需护垫的尿失禁和新发勃起功能障碍仍有少量增加。
局限性
- 中位随访仅21个月(四分位距12-34),证据主要限于短期。
- 使用替代终点构成主要局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Focal therapies (FTs) for localized prostate cancer (PCa) are recommended only within prospective registries or clinical trials. In this systematic review and meta-analysis, we aimed to synthesize data from prospective trials evaluating the efficacy and safety of FTs in patients with clinically localized PCa. METHODS: Systematic searches of the PubMed, Scopus, and Web of Science databases identified prospective studies reporting oncological outcomes of FTs in treatment-naïve, clinically localized PCa patients. The primary endpoint was biopsy-proven clinically significant PCa (csPCa; International Society of Urological Pathology grade group ≥2) recurrence-free survival (csPCa RFS). The secondary endpoints included RFS, radical/systemic treatment-free survival, and adverse event (AE) rates. KEY FINDINGS AND LIMITATIONS: Fifty studies including 4615 patients treated with FTs were analyzed; of these 50 studies, 19 were on predominantly intermediate-risk (n = 2800), 16 on mixed low-/intermediate-risk (n = 990), and 15 on low-risk (n = 825) patients. Estimates of 12- and 24-mo csPCa RFS rates were 86% (95% confidence interval [CI] 82-89%) and 81% (95% CI: 74-86%), respectively. In the intermediate-risk subgroup, the 12-mo csPCa RFS rate was 79% (95% CI: 74-83%). Five-year radical and systemic treatment-free survival was 82% (95% CI: 75-88%). The pooled incidence of grade ≥3 AEs was 3% (95% CI: 2-5%). Pad-requiring urinary incontinence increased by 3% (95% CI: 0-6%), with 11% of patients developing new erectile dysfunction (95% CI: 4-18%). The median follow-up of 21 mo (interquartile range 12-34) and the use of surrogate endpoints constitute the major limitations. CONCLUSIONS AND CLINICAL IMPLICATIONS: The primarily short-term data from prospective studies of FT in clinically localized PCa demonstrate moderate to high cancer control with a favorable safety profile.
引用
- Ślusarczyk A, Gurwin A, Barnaś A, et al. Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. Eur Urol Oncol. 2025. PMID: 40251100. doi:10.1016/j.euo.2025.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。